Thresholds of oxidative stress in newly diagnosed diabetic patients on intensive glucose-control therapy
C (101 MHz, MeOD): 174.48 (C), 172.98 (C), 172.60 (C), 172.27 (C), 171.50 (C), 162.11 (q, J = 35.7 Hz, (C), 135.77 (t, J = 23.8 Hz, CD)), 134.37 (td, J = 25.0, 9.9 Hz, CD), 131.03 (td, J = 25.1, 12.5 Hz, CD), 119.69 (d, J = 86.2 Hz, C), 116.02 (q, J = 284.5 Hz, C) 54.03 (CH), 53.49 (CH), 41.81 (CH 2 ), 40.10 (CH 2 ), 36.20 (CH 2 ), 35.25 (CH 2 ), 32.35 (CH 2 ), 29.44 (CH 2 ), 28.70 (d, J = 16.9 Hz, CH 2 ), 27.05 (CH 2 ), 23.13 (d, J = 4.3 Hz, CH 2 ), 22.67 (d, J = 51.3 Hz, CH 2 )
Intracellular depletion of cAMP and cGMP following their hydrolysis by phosphodiesterase (PDE) enzymes augments inflammatory responses
Over the past few years, we have seen the vital roles the metal nanomedicines play in the GSH-responsive and -exhausting strategies, and inorganic nanomaterials, MOFs, and platinum-based nanomaterials-mediated GSH depletion is expected to realize more powerful synergistic therapy based on rational design